A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-04-13
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-06-17 (study day 58); relationship: not assessed
moderate
assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-08-20 (study day 122); relationship: not assessed
mild
assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-11-16 (study day 210); relationship: not assessed
moderate
assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-05-15 (study day 391); relationship: N
Data queries
No data queries.